Alembic to drive US generics growth after API slump
This article was originally published in Scrip
Executive Summary
Alembic Pharmaceuticals of India expects strong growth in its international generics business, backed, among others, by a string of potential new introductions in the US and supplies under the tender business in Europe. The company is also eyeing the inhalation space, top management said.
You may also be interested in...
Takeda Introduces Vedolizumab In India Amid Signs Of Gear Shift
Takeda launches blockbuster gastrointestinal drug vedolizumab in India, stepping up the tempo on the back of the local base provided by its acquisition of Shire. More expansion in the country appears to be in store for the Japanese firm.
APAC Cancer Preparedness Varied, Late Diagnosis A Key Challenge
A new report on the preparedness of 10 APAC nations to tackle a mounting cancer burden identifies gaps that need to be addressed, saying that a focus on prevention and early diagnosis could help, while also touching on issues around regional drug availability.
Asia Deal Watch: Cipla’s Latest Diabetes Partner In India Is Boehringer Ingelheim
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Need a specific report? 1000+ reports available
Buy Reports